Synthesis of cytochrome c oxidase 2: A p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death

Oncogene

Volumn 31, Issue 33, 2012, Pages 3764-3776

  Wanka, C ^a,b   Brucker, D P ^a,b   Bahr O ^a   Ronellenfitsch, M ^a   Weller, M ^c   Steinbach, J P ^a,b   Rieger, J ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

glioma; hypoxia; p53; respiration; SCO2

Indexed keywords

GLUCOSE; LACTIC ACID; PROTEIN P53; PYRUVIC ACID; PYRUVIC ACID METHYL ESTER; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL HYPOXIA; CELL RESPIRATION; CELL STRESS; COLON CANCER; CONTROLLED STUDY; CYTOCHROME C OXIDASE 2 GENE; ENERGY METABOLISM; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GLIOMA; GLIOMA CELL; GLUCOSE INTAKE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; RESPIRATORY CHAIN; RESPIRATORY FUNCTION; TRANSGENE;

APOPTOSIS; BASE SEQUENCE; CARRIER PROTEINS; CELL HYPOXIA; CELL LINE, TUMOR; CELL RESPIRATION; COLONIC NEOPLASMS; GLIOMA; GLUCOSE; HUMANS; MITOCHONDRIAL PROTEINS; MOLECULAR SEQUENCE DATA; NECROSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865276622     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.530     Document Type: Article

References (53)

1. Anderson AR, Weaver AM, Cummings PT, Quaranta V. (2006). Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127: 905-915. (Pubitemid 44792251)
2. Barnes K, Ingram JC, Porras OH, Barros LF, Hudson ER, Fryer LG et al. (2002). Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). J Cell Sci 115: 2433-2442. (Pubitemid 34752985)
3. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R et al. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120. (Pubitemid 44040989)
4. Bhonde MR, Hanski ML, Notter M, Gillissen BF, Daniel PT, ZeitzM et al. (2006). Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth. Oncogene 25: 165-175. (Pubitemid 43083678)
5. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501. (Pubitemid 28538613)
6. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F et al. (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752. (Pubitemid 47105521)
7. Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A et al. (2011). Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 3: 94ra70.
8. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A et al. (2003). Analysis of the phosphatidylinositol 30-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63: 2742-2746. (Pubitemid 36667143)
9. Corcoran CA, Huang Y, Sheikh MS. (2006). The regulation of energy generating metabolic pathways by p53. Cancer Biol Ther 5: 1610-1613.
10. Curi R, Newsholme P, Newsholme EA. (1988). Metabolism of pyruvate by isolated rat mesenteric lymphocytes, lymphocyte mitochondria and isolated mouse macrophages. Biochem J 250: 383-388. (Pubitemid 18067889)
11. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
12. Dyer BW, Ferrer FA, Klinedinst DK, Rodriguez R. (2000). A noncommercial dual luciferase enzyme assay system for reporter gene analysis. Anal Biochem 282: 158-161. (Pubitemid 30409441)
13. Efeyan A, Serrano M. (2007). p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6: 1006-1010. (Pubitemid 46708570)
14. Ehrmann J, Kolar Z, Kala M, Vojtesek B, Komenda S. (1995). Expression of p53 in glioblastoma multiforme cells: relationship to survival, proliferation and glycosylation. Cesk Patol 31: 87-91.
15. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. (1992). p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 52:674-679.
16. Gatenby RA, Gillies RJ. (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899. (Pubitemid 39472955)
17. Gottlieb E. (2009). Cancer: the fat and the furious. Nature 461: 44-45.
18. Guppy M, Greiner E, Brand K. (1993). The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. Eur J Biochem 212: 95-99. (Pubitemid 23064604)
19. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
20. Jansen M, de Witt Hamer PC, Witmer AN, Troost D, van Noorden CJ. (2004). Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Brain Res Rev 45: 143-163. (Pubitemid 38802868)
21. Jiang BH, Liu LZ. (2008). PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 1784: 150-158.
22. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y et al. (2005). AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293. (Pubitemid 41350534)
23. Kim E, Giese A, Deppert W. (2009). Wild-type p53 in cancer cells: when a guardian turns into a blackguard. Biochem Pharmacol 77: 11-20.
24. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G et al. (2005). Glycolytic enzymes can modulate cellular life span. Cancer Res 65: 177-185. (Pubitemid 40070808)
25. Kopper L, Steel GG. (1975). The therapeutic response of three human tumor lines maintained in immune-suppressed mice. Cancer Res 35: 2704-2713.
26. Leary SC, Kaufman BA, Pellecchia G, Guercin GH, Mattman A, Jaksch M et al. (2004). Human SCO1 and SCO2 have independent, cooperative functions in copper delivery to cytochrome c oxidase. Hum Mol Genet 13: 1839-1848. (Pubitemid 39214332)
27. Leary SC, Sasarman F, Nishimura T, Shoubridge EA. (2009). Human SCO2 is required for the synthesis of CO II and as a thiol-disulphide oxidoreductase for SCO1. Hum Mol Genet 18: 2230-2240.
28. Liu T, Laurell C, Selivanova G, Lundeberg J, Nilsson P, Wiman KG. (2007). Hypoxia induces p53-dependent transactivation and Fas/ CD95-dependent apoptosis. Cell Death Differ 14: 411-421.
29. Ma W, Sung HJ, Park JY, Matoba S, Hwang PM. (2007). A pivotal role for p53: balancing aerobic respiration and glycolysis. J Bioenerg Biomembr 39: 243-246. (Pubitemid 47619376)
30. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O et al. (2006). p53 regulates mitochondrial respiration. Science 312: 1650-1653. (Pubitemid 43902663)
31. Miyamoto S, Murphy AN, Brown JH. (2008). Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ 15: 521-529. (Pubitemid 351267303)
32. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E. (2007). Energy metabolism in tumor cells. FEBS J 274: 1393-1418. (Pubitemid 46333738)
33. Naumann U, Durka S, Weller M. (1998). Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation? Oncogene 17: 1567-1575. (Pubitemid 28472761)
34. Ohgaki H, Kleihues P. (2007). Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445-1453. (Pubitemid 47339290)
35. Puduvalli VK, Sawaya R. (2000). Antiangiogenesis - therapeutic strategies and clinical implications for brain tumors. J Neurooncol 50: 189-200. (Pubitemid 32166301)
36. Rieger J, Bahr O, Muller K, Franz K, Steinbach J, Hattingen E. (2010). Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 99: 49-56.
37. Ryan JJ, Danish R, Gottlieb CA, Clarke MF. (1993). Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol Cell Biol 13: 711-719. (Pubitemid 23006947)
38. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN et al. (2008). Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118: 3930-3942.
39. Steinbach JP, Wolburg H, Klumpp A, Probst H, Weller M. (2003). Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death. Cell Death Differ 10: 823-832. (Pubitemid 36850243)
40. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS et al. (2003). Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9: 493-501. (Pubitemid 36356735)
41. Sung HJ, Ma W, Wang PY, Hynes J, O'Riordan TC, Combs CA et al. (2010). Mitochondrial respiration protects against oxygen-associated DNA damage. Nat Commun 1: 5. doi:10.1038/ncomms1003.
42. Tohma Y, Gratas C, Van Meir EG, Desbaillets I, Tenan M, Tachibana O et al. (1998). Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol 57: 239-245. (Pubitemid 28125504)
43. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE et al. (1994). Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 649-652. (Pubitemid 24068319)
44. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
45. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE et al. (1994). Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 649-652. (Pubitemid 24068319)
46. Vogelstein B, Lane D, Levine AJ. (2000). Surfing the p53 network. Nature 408: 307-310.
47. Warburg O. (1956a). On respiratory impairment in cancer cells. Science 124: 269-270.
48. Warburg O. (1956b). On the origin of cancer cells. Science 123: 309-314.
49. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. (1996). Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-223; discussion 23-4.
50. Wischhusen J, Melino G, Weller M. (2004). p53 and its family members - reporter genes may not see the difference. Cell Death Differ 11: 1150-1152. (Pubitemid 39341641)
51. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. (2003). CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22: 8233-8245. (Pubitemid 37485516)
52. Yoon CH, Lee ES, Lim DS, Bae YS. (2009). PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53. Proc Natl Acad Sci USA 106: 7852-7857.
53. Zhao Y, Chen XQ, Du JZ. (2009). Cellular adaptation to hypoxia and p53 transcription regulation. J Zhejiang Univ Sci B 10: 404-410.